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Background: Toxicity of nanomaterials is one of the most important factors limiting their medi-
cal application. Evaluation of in vitro nanotoxicity allows for the identification and elimination 
of most of the toxic materials prior to animal testing. The current knowledge of the possible side 
effects of biodegradable nanomaterials, such as liposomes and polymeric organic nanoparticles, 
is limited. Previously, we developed a potential drug delivery system in the form of nanocapsules 
with polyelectrolyte, biodegradable shells consisting of poly-l-lysine and poly-l-glutamic acid 
(PGA), formed by the layer-by-layer adsorption technique.
Methods: Hemolysis assay, viability tests, flow cytometry analysis of vascular cell adhesion 
molecule-1 expression on endothelium, analysis of nitric oxide production, measurement of 
intracellular reactive oxygen species levels, detection of antioxidant enzyme activity, and 
analysis of DNA damage with comet assay were performed to study the in vitro toxicity of 
nanocapsules.
Results: In this work, we present the results of an in vitro analysis of toxicity of five-layer 
positively charged poly-l-lysine–terminated nanocapsules (NC5), six-layer negatively charged 
PGA-terminated nanocapsules (NC6) and five-layer PEGylated nanocapsules (NC5-PEG). 
PGA and polyethylene glycol (PEG) were used as two different “stealth” polymers. Of all the 
polyelectrolyte nanocapsules tested for blood compatibility, only cationic NC5 showed acute 
toxicity toward blood cells, expressed as hemolysis and aggregation. Neither NC6 nor NC5-PEG 
had proinflammatory activity evaluated through changes in the expression of NF-κB–dependent 
genes, iNOS and vascular cell adhesion molecule-1, induced oxidative stress, or promoted DNA 
damage in various cells.
Conclusion: Our studies clearly indicate that PGA-coated (negatively charged) and PEGylated 
polyelectrolyte nanocapsules do not show in vitro toxicity, and their potential as a drug delivery 
system may be safely studied in vivo.
Keywords: polyelectrolyte nanocapsules, layer-by-layer, nanotoxicity, oxidative stress, 
genotoxicity
Introduction
Nanotechnology is a broad and rapidly growing field of materials science that is 
revolutionizing industry, research and medicine. One of its branches, nanodiagnostics, 
utilizes quantum dots or semiconductor nanocrystals for cell labeling and for imaging 
purposes.1,2 Various nanomaterials have gained attention as non-viral delivery systems 
for gene therapy.3 Finally, nanopharmacology offers novel solutions for vaccine or drug 
formulations to improve their bioavailability, biodistribution and pharmacokinetic sta-
bility, while reducing their toxicity against healthy tissues. Despite the enormous con-
tribution to the development of nanomaterials for medical applications, the number of 
nanotherapies approved by the US Food and Drug Administration is still low.4 The most 
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important factor that hampers the therapeutic use of many 
nanomaterials is their own acute and chronic toxicity. The 
acute effects may be manifested by hemolysis of erythrocytes, 
aggregation of platelets or leukocytes, triggering coagulation 
cascade and decreasing the viability of various normal cells. 
Chronic effects comprise, among others, the inflammatory 
and antigenic response, oxidative stress and DNA damage 
that may finally cause allergy, cardiovascular diseases or 
cancer.5 In recent years, more research has been focused on 
the development of biodegradable organic nanomaterials 
that are degraded in the body to the cell building blocks 
such as sugars, amino acids, fatty acids or nucleotides.6 
Biodegradable nanomaterials are implicitly assumed to be 
nontoxic, and much less attention is paid to their potential 
side effects than to those of inorganic ones. However, the 
detailed toxicity studies should comprise all nanomaterials 
designed for therapies because nanotoxicity results not only 
from the chemical composition of a nanoparticle, but also 
from its physical properties including size, shape, charge, as 
well as surface decoration.7
The functionalization of a nanoparticle surface with 
hydrophilic polymers is an approach for extending nanomate-
rial circulating lifetime, enhancing its delivery and retention 
in the target tissues, and decreasing its systemic toxicity. 
The improvement of the pharmacokinetic profile observed 
after surface decoration is primarily due to diminished nano-
material aggregation and interactions with serum opsonins, 
which accelerate nanoparticle phagocytosis by monocytes 
and macrophages. Additionally, lower systemic toxicity of 
modified nanoparticles may be a consequence of their weaker 
interactions with red blood cells (RBCs) and decreased level 
of hemolysis. Currently, polyethylene glycol (PEG) is the 
polymer most often used for nanomaterial functionalization. 
Alternative strategies replacing PEG with poly-amino acids, 
for example, poly-l-glutamic acid (PGA), have been also 
recently implemented.8
One of the most promising methods of nanocarrier 
formation is the layer-by-layer (LbL) technique originally 
proposed by Sukhorukov et al and based on sequential, 
alternate adsorption of positively and negatively charged 
nano-objects on a colloidal core.9 This strategy allows 
forming polyelectrolyte nanocarriers containing active 
compounds, for example, drugs. In recent years, various 
polyelectrolyte nanoparticles composed of, for example, 
chitosan, poly(2-acrylamido-2-methylpropanesulfonic acid), 
poly-l-lysine (PLL) and poly(ethylene glycol)-poly(l-
lysine)-poly(lactic acid), have been explored as promising 
carriers for the delivery of anticancer compounds, such as 
curcumin,10 doxorubicin11 or camptothecin,12 as well as pho-
tosensitizers for photodynamic therapy.13
Our previous studies pointed to the polyelectrolyte 
nanocapsules formed by encapsulation of nanoemulsion 
droplets in multilayer shells of poly-amino acids, namely 
PLL and PGA, as a promising candidate for a drug delivery 
system. We characterized nanoparticles similar in size, 
but differing in charge and surface decoration with PEG 
and found that both negatively charged as well as close to 
neutral, PEGylated empty polyelectrolyte nanocapsules did 
not affect the viability of various cell types. However, drugs 
encapsulated in those nanomaterials possessed biological 
activity comparable to or better than the carrier-free drug 
formulations.14,15 Moreover, using confocal microscopy we 
demonstrated that fluorescently labeled non-PEGylated and 
PEGylated nanocapsules are internalized by different cells, 
with most of the internalized nanocapsules taken up by the 
lysosomes.14,16,17
Here, we present the results of in vitro studies of PLL-
terminated, PGA-terminated and PEGylated, five to six 
layer polyelectrolyte nanocapsules which were performed 
to predict their potential in vivo toxicity after intended 
intravenous administration. Two out of three tested nano-
capsules, namely PGA-terminated six-polyelectrolyte layer 
nanocapsules (NC6); PEGylated five-polyelectrolyte layer 
nanocapsules (NC5-PEG), passed all in vitro tests, showing 
no undesired effects, which indicates the validity of their 
further in vivo evaluation.
Materials and methods
chemicals for polyelectrolyte 
nanocapsules synthesis
All purchased reagents were used without any further 
purification. The polyelectrolytes, PLL hydrobromide, 
PLL (MW ~15,000–30,000), PGA sodium salt, PGA 
(MW ~15,000–50,000), surfactant, the solvent docusate 
sodium salt (AOT), and chloroform, as well as sodium 
chloride were obtained from Sigma-Aldrich. PEGylated 
polyelectrolyte poly(l-lysine)-graft-poly(ethylene glycol) 
PLL (20,000)-g-PEG (5,000) was purchased from SuSoS 
(Dübendorf, Switzerland). Ultrapure water was obtained 
using the Millipore Direct-Q5 UV purification system.
Materials for biological analysis
All reagents for cell culture were obtained from Lonza. 
Ficoll-Paque Plus used for peripheral blood mononuclear 
cell (PBMC) isolation was provided by GE Healthcare. MTT, 
lipopolysaccharide (LPS), sulphanilic acid, N-(1-naphtyl) 
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ethylenediaminedihydrochloride, 2′7′-dichlorofluorescin 
diacetate (DCFH-DA) nitroblue tetrazolium, riboflavin, 
etoposide, Drabkin’s reagent, BRIJ® L23 solution, bovine 
hemoglobin, Dulbecco’s PBS (DPBS), N,N,N′,N′-tetrame-
thylethylenediamine and phorbol 12-myristate 13-acetate 
(PMA) were purchased from Sigma-Aldrich. Mouse inter-
feron γ (IFN-γ) was obtained from R&D Systems. Home-
made recombinant human tumor necrosis factor (TNF) was 
purified from the culture media of mouse fibroblasts stably 
expressing TNF by affinity chromatography on anti-TNF 
monoclonal antibody conjugated to Sepharose. Biological 
activity of TNF was standardized using human TNF provided 
by Sigma-Aldrich. Lack of LPS contamination was verified 
with E-TOXATE kit (Sigma-Aldrich).
Nanocapsules preparation
Multilayer polyelectrolyte nanocarriers, NC5 (PLL-terminated 
five-polyelectrolyte layer nanocapsules), NC6 (PGA-termi-
nated six-polyelectrolyte layer nanocapsules) and NC5-PEG 
(PEGylated five-polyelectrolyte layer nanocapsules), were syn-
thesized by the method developed previously.18 Nanoemulsion 
droplets were formed by dispersing 0.1 mL of oil phase (chloro-
form containing AOT 34 mg/mL) into 200 mL aqueous phase 
(polycation solution PLL 0.1 mg/mL, 15 mM NaCl). Subse-
quently, the formed nanoemulsion droplets were encapsulated 
in polyelectrolyte multilayer shell using the LbL technique with 
saturation approach as described in detail previously. The vol-
umes of polyelectrolytes used for the formation of consecutive 
layers of the multilayer shell were as follows: 1 mL PGA, 1.3 
mL PLL, 1.5 mL PGA, 3 mL PLL, 3.5 mL PGA (all polyelec-
trolytes at the concentration 2 mg/mL). To form PEGylated 
nanocapsules, PGA-terminated four-layer nanocapsules were 
coated with a layer of PLL-g-PEG using the same procedure 
as for normal polyelectrolyte.14 Chloroform was evaporated 
under reduced pressure and its final concentration measured 
by gas chromatography with an electron capture detector 
was ~0.04 mg/L.16 The stability of nanocapsules was evaluated by 
the periodic measurements of their size and zeta potential.
Nanocapsules characterization
The size distribution was determined by dynamic light 
scattering, while the zeta potential was determined by Laser 
Doppler Electrophoresis, both using Zetasizer Nano Series 
from Malvern Instruments. The nanocapsules concentration 
was determined by Nanoparticle Tracking Analysis using 
NanoSight NS500 (Malvern Instruments). The obtained 
values were an average of at least three measurements. 
All measurements were performed at 25°C in 15 mM NaCl. 
Nanocapsules were also visualized by Cryo-Scanning Electron 
Microscopy using Jeol JSM 7600F field emission scanning 
electron microscope FESEM (Jeol Ltd, Tokyo, Japan) 
according to the protocol described previously.14
cells, cell cultures and the concentration 
of nanocapsules
Human hepatoma-derived HepG2 cell line (ATCC® HB-8065) 
and mouse macrophage cell line P388D1 (ATCC® CCL-46) 
were obtained from American Type Culture Collection. 
Murine brain endothelial MBE cells were a gift from 
R Auerbach (University of Wisconsin, Madison, WI, USA). 
Their use was approved by the Animal Welfare Committee at 
the Faculty of Biochemistry, Biophysics and Biotechnology, 
Jagiellonian University, pursuant to the Polish and European 
legal acts. Citrated human blood from healthy volunteers was 
purchased from the Regional Center of Blood Donation and 
Treatment in Kraków, Poland. Regional Center of Blood 
Donation and Treatment deidentified blood materials as 
appropriate for the confidentiality assurance of human 
subjects. Thus, this study adheres to appropriate exclusions 
from the approval of human subjects.
All cells were cultivated in an incubator (5% CO
2
, 
37°C, .95% humidity). The final concentration of nanocap-
sules used in all biological experiments was ~2×1011/mL. From 
our previous studies, it is clear that this concentration of nano-
capsules is necessary to deliver a closed drug in amounts com-
parable to those applied as nanocarrier-free formulations.14,19
hemolytic activity of polyelectrolyte 
nanocapsules
Analysis of the hemolysis of human erythrocytes was 
performed according to the procedure proposed by 
Dobrovolskaia et al.20 Plasma-free hemoglobin and total 
blood hemoglobin (TBH) were measured spectrophoto-
metrically at 540 nm using a microplate reader after reaction 
with cyanmethemoglobin reagent (Drabkin’s reagent). Next, 
the entire blood samples were diluted with DPBS to adjust 
the total hemoglobin concentration to 10 mg/mL (diluted 
TBH [dTBH]). Aliquots of 0.1 mL of erythrocyte suspen-
sions (dTBH) were mixed with 0.8 mL of DPBS and with 
1) 0.1 mL of 15 mM NaCl (hemolysis of untreated RBC), 
or 2) 0.1 mL of Triton X-100 (4% v/v, positive control of 
hemolysis), or 3) 0.1 mL of NC5 nanocapsules, or 4) 0.1 mL 
of NC6 or 5) 0.1 mL of NC5-PEG, and incubated at 37°C for 
3 hours with gentle shaking. Erythrocyte morphology was 
analyzed using inverted light microscope LeicaDM IL LED 
Fluo. The cells were centrifuged (1,500×g, 5 minutes) and 
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the concentration of the released hemoglobin was determined 
(defined as “sample” in the following formula). The level of 
hemolysis was calculated as follows:
 
% 
[ ] 
[ ] 
100%hemolysis
Hb sample
Hb dTBH
= ×
 
cytotoxicity assay for PBMcs
Human PBMCs were isolated from the blood of different 
healthy donors using Ficoll-Paque Plus gradient fraction-
ation according to the manufacturer’s protocol and stored 
at -80°C in fetal bovine serum (FBS) containing 10% 
dimethyl sulfoxide. Prior to experiments, thawed PBMCs 
were cultivated in 96-well plates at a density of 1×105/well 
in 100 µL of growth medium (RPMI supplemented with 
antibiotics [100 U/mL penicillin, 100 µg/mL streptomycin] 
and 20% FBS). The next day, the medium was replaced with 
fresh growth medium containing additionally: 1) 1.5 mM 
NaCl, 2) NC5, 3) NC6 and 4) NC5-PEG. After 48 hours, 
the viability of PBMCs was estimated by the trypan blue 
dye exclusion test. All cells and dead cells were counted 
in Bürker’s chamber. The percentage of the dead cells was 
calculated according to the formula:
 
% 100% dead cell
Dead cell number
Total cell number
= ×
 
Morphological changes were analyzed using the inverted 
light microscope LeicaDM IL LED Fluo.
MTT assay
P388D1 and MBE cells were grown in DMEM (4.5 g 
glucose/L), while HepG2 cells were grown in DMEM (1 g 
glucose/L); both media contained 10% FBS and antibiotics. 
For experiments, the cells were seeded on 96-well plates in 
100 µL of growth medium (density of 5×103/well for P388D1 
and HepG2, and 2×104/well for MBE). After 48 hours, the 
media were replaced with fresh ones containing 1) 1.5 mM 
NaCl, 2) NC5, 3) NC6 and 4) NC5-PEG. After 48 hours, the 
cell morphology was examined and the viability of the cells 
was determined by MTT assay according to the standard 
protocol.21 Cell viability was calculated using the following 
formula (where A545 is absorbance measured at 545 nm.):
 
Cell viability control
A sample
A untreated ce
 (% )
 ( )
 
545
545
=
( lls)
100%×
 
Analysis of the influence of the 
nanocapsules on nitric oxide (NO) 
production
P388D1 (1.5×104/well) and MBE (4×104/well) cells were 
grown in 96-well plates in DMEM supplemented with 5% 
FBS and antibiotics. The next day, the medium was replaced 
with DMEM supplemented with 2% FBS and antibiotics, and 
in order to stimulate inducible nitric oxide synthase (iNOS) 
expression, it was replaced with LPS and/or cytokines. In the 
case of P388D1, the groups contained 1) 1.5 mM NaCl, 
2) NC6, 3) NC5-PEG, 4) LPS (100 ng/mL), 5) LPS+NC6, 
6) LPS+NC5-PEG, 7) IFN-γ (10 ng/mL), 8) IFN-γ+NC6, 
9) IFN-γ+NC5-PEG, 10) LPS+IFN-γ, 11) LPS+IFN-γ+NC6 
and 12) LPS+IFN-γ+NC5-PEG. For MBE cells, the same 
scheme was applied except that TNF (10 ng/mL) was used 
instead of LPS. The nitrite levels in the culture media 
(100 µL) were measured after 24 hours using 100 µL 
of Griess reagent (1% [w/v] sulfanilic acid/0.1% [w/v] 
N-(1-naphtyl) ethylenediaminedihydrochloride [Sigma] 
in 2.5% [v/v] H
3
PO
4
). The absorbance was measured at 
545 nm using a microplate reader (Versa Max, SoftMaxPro; 
Molecular Devices).
analysis of vascular cell adhesion 
molecule-1 (VcaM-1) expression
MBE cells were grown in 12-well plate (2×105 cells/well) in 
DMEM enriched with 10% FBS and antibiotics. The next day, 
the cells were incubated for 24 hours in DMEM containing 2% 
FBS, and TNF (10 ng/mL) or NC6 or NC5-PEG. Then the 
cells were washed with PBS, detached from plates with 
accutase and stained with phycoerythrin (PE)-conjugated 
rat anti-VCAM-1 IgG according to the protocol provided 
by the antibody supplier (Pharmingen, PE Rat-Anti-Mouse 
CD106 Clone 429; BD Biosciences). VCAM-1 expression 
was analyzed by flow cytometry using BD FACSCalibur flow 
cytometer and CellQuestPro software (Becton Dickinson).
Detection of reactive oxygen species
The amount of reactive oxygen species (ROS) was measured 
using the DCFH-DA assay. HepG2 cells were seeded at 
1.5×104 cells/well in a 96-well sterile plate with transparent 
and flat bottom for fluorescent assay in 100 µL of growth 
medium. The next day, the medium was replaced with fresh 
growth medium containing 1) 1.5 mM NaCl, 2) NC6 and 
3) NC5-PEG, and the cells were incubated for the next 2, 
6 or 24 hours. After removal of the medium, staining with 
25 µM DCFH-DA in PBS was performed for 30 minutes 
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(in dark, room temperature [RT]), followed by addition 
of 100 µL of 1 mM H
2
O
2
 in PBS to half of the wells for 
another 30 minutes (RT, in dark). The staining solution was 
discarded, cells were washed once with PBS and 100 µL of 
PBS was added to each well. Fluorescent area scan read-
ing (number of points horizontal × vertical=5×5, excitation 
470 nm, emission 535 nm) was performed using Synergy H1 
hybrid reader and analyzed with Gene5 Software (BIOTEK 
Instruments). A mean fluorescence intensity of 100% cor-
responds to fluorescence intensity measured for HepG2 
incubated with NaCl prior to DCFH staining.
analysis of superoxide dismutase (sOD) 
activity
HepG2 cells were grown overnight in a 12-well plate 
(2×105 cells/well, in 1 mL of growth medium). Prior to the 
experiment, the medium was replaced with a fresh one con-
taining 1) 1.5 mM NaCl, 2) NC6, 3) NC5-PEG and 4) PMA 
(100 ng/mL, positive control). After 24 hours, HepG2 cells 
were trypsinized, resuspended in 25 µL of PBS, subjected to 
repeated freeze–thaw cycles to release cellular proteins and 
centrifuged. The extracted proteins (5 µg) were separated on 
12% polyacrylamide gel (native conditions, 1.5 hours, 20 V/
cm, room temperature [RT]). The gels were stained for 20 
minutes at RT in staining solution (50 mM phosphate buffer 
pH 7.4, 10 mM EDTA, 0.25 mM nitroblue tetrazolium, 28 mM 
N,N,N′,N′-tetramethylethylenediamine and 30 µM riboflavin). 
Gel analysis was performed with Fusion F×5 (Vilber).
comet assay
DNA damage was measured by electrophoretic fractionation 
of single cells in agarose gel. P388D1 (4×104 cells/well), 
PBMC (1×105 cells/well) and HepG2 (8×104 cells/well) 
cells were incubated for 2, 24 or 48 hours with 1.5 mM 
NaCl or with different nanocapsules: NC6 or NC5-PEG. 
Etoposide was used as a DNA damage inducer (25 µM for 
PBMC, 10 µM for HepG2 and 1 µM for P388D1). After 
incubation, the cells were collected from plates and mixed 
with low-melting-point agarose (0.1% agarose, 37°C). Then, 
10,000 cells in 100 µL of agarose were smeared on slides 
precoated with a layer of 1% normal melting point agarose. 
Cells were lysed, DNA was alkali denatured and subjected 
to electrophoresis (0.74 V/cm, 300 mA) for 30 minutes at 
4°C in 300 mM NaOH, 1 mM EDTA buffer and analyzed 
as described by Kyzioł et al.22 The percentage of DNA in the 
tail (% DNA damage) was determined from two slides per 
sample with 50 randomly selected cells per slide.
statistical analysis
Statistical significance was analyzed by the Mann–Whitney 
U test using Origin 2018 Pro software, with P,0.05 being 
considered significant. Bars represent the mean±SD from at 
least three independent experiments performed using nano-
materials from two different syntheses.
Results
synthesis and characterization of 
polyelectrolyte nanocapsules
Nanoemulsion droplets (size ~100 nm and polydisper-
sity index ,0.2; Figure 1A) stabilized by the surfactant/
polyelectrolyte (AOT/PLL) interfacial complex that provides 
favorable condition for nanoemulsification and simultane-
ously stable surface charge for polyelectrolyte adsorption23 
were formed according to the procedure described in the pre-
vious section. The zeta potential of formed droplets was high 
enough (+64 mV) to provide sufficient electric stabilization 
against their aggregation. Polyelectrolyte (PGA, PLL and 
PLL-g-PEG) multilayer shells were constructed by the LbL 
approach on the nanodroplets formed. The adsorption of 
consecutive PGA and PLL layers resulted in changes in 
zeta potential values arranged in the typical saw-like pattern 
(average zeta potential: +40 mV for NC5 and -40 mV for 
NC6), while the adsorption of PEGylated polyelectrolyte 
(PLL-g-PEG) decreased the zeta potential to values close to 
zero (4±5 mV), as shown in Figure 1B. The average sizes 
from three different batches of NC5, NC6 and NC5-PEG cap-
sules are presented in Table 1. Moreover, the size of nanocap-
sules visualized by the cryo-Scanning Electron Microscopy 
was in good agreement with the values obtained by dynamic 
light scattering, as can be seen in Figure 1C. The particle con-
centration as determined by Nanoparticle Tracking Analysis 
was ~2×1012/mL. Stability studies of the nanocapsules (in 
15 mM NaCl, 25°C) indicated no significant changes in 
their size and zeta potential during the period of 60 days.
Negatively charged and Pegylated 
nanocapsules are not toxic for human 
rBcs and PBMcs
Numerous nanoparticle types were found to interact with vari-
ous blood components (erythrocytes, leukocytes, platelets or 
plasma proteins), which led to toxicity manifestations, such as 
hemolysis, blood coagulation or secretion of proinflammatory 
mediators.24,25 Thus, the first experiments were set to examine 
the influence of each type of tested polyelectrolyte nanocapsules 
on the viability of human PBMCs and erythrocytes. PBMCs 
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isolated from healthy adult donors were exposed to NC5, NC6 
and NC5-PEG for 48 hours, and then, the number of dead cells 
was determined by trypan blue exclusion test. We observed a 
relatively high percentage (25%) of dead cells in the control 
sample, probably due to freeze–thaw procedure. In contrast 
to NC6 or NC5-PEG, which did not affect cell viability, posi-
tively charged PLL-terminated NC5 exerted strong cytotox-
icity against human PBMCs, increasing the number of dead 
cells to 61% (Figure 2A). The cytotoxic effect of NC5 was 
accompanied by PBMC aggregation. Interestingly, negatively 
charged PGA-terminated NC6 induced significant changes in 
the morphology of a subpopulation of PBMC. The observed 
changes in morphology are typical for monocytes that 
undergo phagocytosis and, most probably, the subpopulation 
includes nanocapsule-loaded monocytes. In contrast, PEGy-
lated nanocapsules had no influence on PBMC morphology.
Similar to the results with PBMCs, only NC5 showed sig-
nificant cytotoxicity toward erythrocytes in hemolytic assay. 
As presented in Figure 2B, after 3 hours of exposure of eryth-
rocytes to NC5, the cells became aggregated and .10% of 
hemoglobin was released; according to Dobrovolskaia and 
McNeil,26 negligible amounts of hemoglobin (,2%) were 
released in response to NC6 and NC5-PEG.
Due to significant cytotoxicity of positively charged NC5 
used in the concentration ~2×1011/mL, we excluded these 
nanocapsules from further studies.
Polyelectrolyte nanocapsules do not 
induce proinflammatory response in vitro
Monocytes, macrophages and endothelial cells are the most 
prominent cells in inflammation. Therefore, we evaluated 
the possible proinflammatory activity of polyelectrolyte 
nanocapsules using mouse monocyte-macrophage cell line 
P388D1 and mouse brain endothelial MBE cells.
First, we verified that neither NC6 nor NC5-PEG had 
any influence on the morphology and viability of P388D1 
and MBE cells incubated for 48 hours with nanocapsules 
(Figures 3A and S1). The levels of NO produced by iNOS, 
the expression of which is triggered in response to proin-
flammatory factors, is a useful and easy-to-measure marker 
of inflammation. Efficient expression of iNOS requires two 
stimulators: LPS and IFN-γ are the best pair for monocytes 
and macrophages, including P388D1, while TNF and IFN-γ 
are the best pair for MBE cells. To evaluate whether tested 
nanocapsules may affect in any way (trigger, potentiate, 
inhibit) the expression of iNOS, we incubated P388D1 
and MBE cells for 24 hours with 1) NC6 or NC5-PEG or 
Figure 1 characterization of polyelectrolyte nanocapsules used in this study.
Notes: (A) an example of size distribution of Nc1–Nc6 and Nc5-Peg measured by Dls. (B) The dependence of zeta potential of nanocapsules on a number of layers in 
the polyelectrolyte shell. (C) The cryo-seM micrograph of six-layer nanocapsules. representative data for two different nanocapsule preparations used in this study.
Abbreviations: Dls, dynamic light scattering; Nc1, nanoemulsion droplets; Nc2, two-layer nanocapsules; Nc3, three-layer nanocapsules; Nc4, four-layer nanocapsules; 
NC5, five-layer nanocapsules; NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; SEM, scanning electron microscopy.
Table 1 The average size from three different batches of Nc1 
(Pll-terminated, one polyelectrolyte layer nanocapsules), Nc5, 
Nc6 and Nc5-Peg
Nanocapsules Size (nm)
Nc1 100±10
Nc5 110±15
Nc6 115±15
Nc5-Peg 125±10
Note: Data are presented as mean ±sD.
Abbreviations: NC1, nanoemulsion droplets; NC5, five-layer nanocapsules; 
NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; PEG, 
polyethylene glycol; Pll, poly-l-lysine.
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2) a single iNOS stimulator or 3) a pair of stimulators in the 
absence or presence of tested nanomaterials, and measured 
the levels of nitrite (product of spontaneous NO oxidation) 
in cell culture media. We observed that nanocapsules neither 
induced production of NO by themselves nor enhanced the 
effect of single stimulators of iNOS transcription, that is, 
they did not provide the second proinflammatory signal 
(Figure 3B). They also did not affect the increased levels of 
NO produced by iNOS expressed in response to either pair 
of stimulators in P388D1 and MBE cells.
To confirm that the lack of effect of nanocapsules on 
inflammation is not limited to iNOS expression and NO 
synthesis, we also evaluated their possible impact on the 
expression of another marker of cytokine-mediated endothe-
lial activation, namely VCAM-1. Flow cytometry analysis 
showed that, in contrast to TNF, a strong stimulator of 
VCAM-1 expression, neither NC6 nor NC5PEG was able to 
stimulate VCAM-1 expression in MBE cells over the basal 
level (Figure 3C).
Oxidative stress is not observed in 
hepg2 cells exposed to polyelectrolyte 
nanocapsules
Generation of ROS resulting in oxidative stress is one of the 
well-characterized mechanisms of nanomaterial toxicity. 
We analyzed the possible effect of polyelectrolyte nano-
capsules on ROS formation in HepG2 cell line, which is a 
suitable model for the detection of oxidative stress induced 
by different agents including nanomaterials.27
After verifying that NC6 and NC5-PEG did not affect 
HepG2 morphology or viability (Figures 4A and S1), we 
estimated the levels of ROS generation in HepG2 using 
DCFH-DA assay. HepG2 cells were exposed to NaCl or 
nanocapsules for 2, 6 or 24 hours and then stained with 
DCFH-DA. After staining, the HepG2 cells were also 
exposed to PBS or H
2
O
2
 for 30 minutes. This approach allows 
not only the analysis of nanomaterial-mediated ROS forma-
tion, but also the verification of whether nanocapsules affect 
normal cellular response to ROS by inhibiting or stimulating 
antioxidative enzyme activity.
However, neither basal nor increased, via H
2
O
2
, levels of 
ROS were affected by 2-, 6- or 24-hour incubation of HepG2 
cells with NC6 or NC5-PEG nanocapsules (Figure 4B). The 
lack of induction of oxidative stress by the nanomaterials was 
also confirmed by zymographic analysis of the activity of 
antioxidant enzyme, SOD. Mitochondrial manganese SOD 
(Mn-SOD) is a major ROS-scavenging enzyme in the cell. 
Therefore, upregulated expression and activity of Mn-SOD 
may be used as a very sensitive indicator of intracellular 
ROS.28 Unlike PMA, a known activator of Mn-SOD expres-
sion, neither NC6 nor NC5-PEG influenced Mn-SOD activity 
in HepG2 cells (Figure 4C).
Polyelectrolyte nanocapsules are not 
genotoxic
Finally, we analyzed potential genotoxicity of polyelectro-
lyte nanocapsules. We measured the levels of DNA damage 
in PBMC, P388D1 and HepG2 cells cultured for 2, 24 or 
A
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NaCI NC5
*
PBMC viability
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d 
ce
lls
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)
NC6 NC5-PEG
50 µm
B
100
20
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NaCI NC5Triton
X-100
*
*
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H
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)
NC6 NC5-PEG
50 µm
Figure 2 analysis of the effect of polyelectrolyte nanocapsules on human PBMcs and erythrocytes.
Notes: (A) Viability of PBMcs. PBMcs were incubated for 48 hours with 1.5 mM Nacl or with different nanocapsules (~2×1011/ml). all cells and dead cells were 
counted. (B) Detection of nanomaterial-induced hemolysis. rBcs were exposed for 3 hours to 1.5 mM Nacl or different nanocapsules or Triton X-100. Detection of 
hemoglobin was performed spectrophotometrically. Morphological changes were analyzed using inverted light microscope. arrows indicate cell aggregates or cells with 
changed morphology. *P,0.05.
Abbreviations: NC5, five-layer nanocapsules; NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; PBMC, peripheral blood mononuclear cell; 
Peg, polyethylene glycol; rBc, red blood cell.
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48 hours in the presence or absence of nanocapsules, NC6 
or NC5-PEG. Etoposide, a known DNA damage-inducing 
agent, was used as positive control. DNA strand breaks were 
measured after agarose gel electrophoresis of single cells. 
In contrast to etoposide, neither NC6 nor NC5-PEG increased 
the levels of DNA damage in any cell type and after any 
incubation period, strongly suggesting that the nanocapsules 
are not genotoxic (Figure 5).
Discussion
Intravenous administration is one of the most common routes 
of nanomaterial delivery. Thus, evaluation of the interplay 
between nanoparticles and blood components is considered 
as an important step in the development of nanomaterial 
drug carriers. Numerous reports indicated that different 
nanoparticles tend to directly interact with blood proteins 
and cells and may thus induce acute toxicity manifesting 
primarily in hemolysis, platelet aggregation, or severe proin-
flammatory response leading in extreme cases to serious, 
life-threatening events.29
Of all the polyelectrolyte nanocapsules tested for blood 
compatibility, only cationic PLL-terminated NC5 showed 
acute toxicity toward blood cells. They induced aggregation 
of both RBCs and PBMCs; aggregation of RBCs was accom-
panied by substantial hemolysis. We believe that, similar 
to the observations of Ziemba et al, the hemolytic activity 
of positively charged NC5 results from direct interaction 
with erythrocytes, which, due to a high surface expression 
γ
α
γ α
α
α
γ
γ
Figure 3 Analysis of inflammatory response to nanocapsules.
Notes: (A) Viability of mouse macrophage cell line P388D1 and endothelial MBe cells. The cells were incubated for 48 hours in growth medium with 1.5 mM Nacl 
or nanocapsules (~2×1011/ml). (B) analysis of NO production by iNOs. Nitrite levels were measured by griess reaction after 24 hours incubation of the cells with 
1) nanocapsules or Nacl (NT), 2) lPs or cytokines and 3) nanocapsules and lPs or cytokines. (C) Flow cytometry analysis of VcaM-1 expression on MBe cells. MBe cells 
were incubated for 24 hours with nanocapsules or with TNF and then stained with anti-VcaM-1 antibody. *P,0.05
Abbreviations: LPS, lipopolysaccharide; MFI, mean fluorescence intensity; NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; NO, nitric oxide; 
Peg, polyethylene glycol; TNF, tumor necrosis factor; VcaM, vascular cell adhesion molecule.
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of glycoproteins and glycolipids rich in sialic acid, display 
strong negative charge resulting in electrostatic repulsion 
between cells.30 Thus, cationic nanomaterials interacting with 
erythrocyte surface may induce hemorheological alterations, 
aggregation and membrane destabilization, which leads to 
cell rupture and hemoglobin release.31 The charge-directed 
interactions of NC5 with PBMCs may also explain the aggre-
gation and diminished viability of the cells. It is worth noting 
that NC5 was not toxic to P388D1, MBE and HepG2 cells 
(data not shown). Although our results indicate that cationic 
NC5 used in the concentration ~2×1011/mL exhibited strong 
cytotoxicity against human blood cells, there are in vivo 
studies demonstrating that cationic nanomaterials composed 
of PLL but used in a lower concentration are safe and may 
be considered as promising nanomaterials with medical 
relevance. For example, Al-Jamal et al showed that cationic 
PLL dendrimers used to inhibit tumor vascularization or to 
deliver doxorubicin had safe toxicological profile in mouse 
models of cancer.32,33 Similarly, Ayyappan et al performed 
detailed toxicity studies of PLL nanocapsules in rats, 
Figure 4 analysis of potential nanoparticle-mediated oxidative stress.
Notes: (A) Viability of human hepatocellular cell line hepg2. cells were exposed to nanocapsules for 48 hours. (B) analysis of rOs generation. hepg2 cells were grown for 
2, 6 or 24 hours in media containing 1.5 mM Nacl or nanocapsules. Intracellular rOs were measured after staining the cells with DcFh-Da (white bars) or with DcFh-Da 
followed by incubation with 1 mM h2O2 (gray bars). (C) analysis of sOD activity by native Page-based zymography. hepg2 cells were exposed to nanocapsules or PMa. 
The upper band corresponds to rOs-inducible Mn-sOD activity and the lower band to the activity of constitutively expressed cuZn-sOD. The representative zymogram of 
three independent experiments performed is shown. concentration of nanocapsules in these experiments was ~2×1011/ml.
Abbreviations: DcFh-Da, 2′7′-dichlorofluorescin diacetate; NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; PAGE, polyacrylamide gel 
electrophoresis; Peg, polyethylene glycol; PMa, phorbol 12-myristate 13-acetate; rOs, reactive oxygen species; sOD, superoxide dismutase; w/o, without.
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demonstrating immunocompatibility and low toxicity of 
these nanocapsules.34
In contrast to NC5, negatively charged PGA-terminated 
NC6 did not cause RBC aggregation and hemolysis. How-
ever, although NC6 did not influence PBMC viability, 
it affected the morphology of monocytes within PBMC 
population, most probably by increased phagocytosis of 
the nanomaterial. This phenomenon was not observed for 
PEGylated NC5 and the difference may be significant when 
considering PGA as an alternative to PEG for decoration of 
nanocapsules’ surface.
It was found that the efficiency of nanoparticles phago-
cytosis was correlated with their tendency to bind proteins. 
Thus, our present results are in agreement with those previ-
ously published which demonstrated that the interactions of 
nanocapsules with human serum albumin were strong for 
NC5, far weaker for NC6 and negligible for NC5-PEG, since 
it was shown that nanoparticles that strongly interact with pro-
teins are more prone to phagocytosis.14,17 Decreased in vitro 
toxicity of PEGylated nanomaterials compared to unmodified 
ones, which may result from diminished uptake of PEG-
decorated nanoparticles, has been demonstrated, for example, 
for PEGylated cationic liposome–DNA complexes.35 On the 
other hand, PEG was shown to be immunogenic in mice and 
humans. The presence of anti-PEG antibodies in circulation 
may induce fast clearance of the nanomaterial and decrease 
its target tissue accumulation. Thus, application of other 
hydrophilic, non-immunogenic polymers, for example, PGA, 
for nanocapsules decoration could be the answer to the immu-
nogenicity issue. PGA is an external layer of NC6. Although 
neither NC6 nor NC5-PEG showed any signs of cytotoxicity, 
NC6 had some influence on monocyte morphology. Only in 
vivo studies may verify which of the two nanocapsules are 
more suitable as drug carriers.
Data concerning the influence of biodegradable nanoma-
terials on PBMC and erythrocytes are scarce. Mendes et al 
observed that among different negatively charged polymeric 
nanomaterials (nanocapsules, nanospheres and liposomes), 
only nanostructured lipid carriers induced hemolysis of 
human red cells and decreased the viability of PBMCs.36 Our 
polycationic NC5 was not toxic toward several normal cell 
lines and its strong side effects were demonstrated only when 
its influence on erythrocytes and PBMCs was analyzed. The 
results clearly indicate the necessity to evaluate the impact 
of biodegradable nanomaterials on blood cells.
Proinflammatory activity of nanomaterials is another 
limiting factor in their clinical application. Nuclear factor-κB 
(NF-κB), a transcription factor promptly activated by 
various inflammatory stimuli, plays a crucial role in the 
development of inflammation by stimulating the expression 
of proinflammatory factors including cytokines, adhesion 
molecules and iNOS. Changes in NF-κB activity in response 
Figure 5 Quantification of DNA breaks after exposure of PBMC, P388D1 and HepG2 cells to nanocapsules – comet assay. The cells were cultured for 2, 24 or 48 hours in 
media containing 1.5 mM Nacl or nanocapsules (~2×1011/ml) or etoposide. *P,0.05.
Abbreviations: NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; PBMC, peripheral blood mononuclear cell; PEG, polyethylene glycol.
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to a nanomaterial are often regarded as an indicator of its 
influence on inflammatory response. To verify whether 
polyelectrolyte nanocapsules affect NF-κB activity, we 
analyzed the expression of two NF-κB–dependent markers 
of inflammation, namely iNOS and VCAM-1. Measure-
ment of nanomaterial-stimulated NO levels was already 
used to characterize the biological effects of some inorganic 
particles. For example, Hassanpour et al demonstrated that 
nanosilver colloid upregulates NO synthesis in different 
cell types.37 This phenomenon may arise from activation of 
p38 mitogen-activated protein kinase38 or increased levels 
of ROS generated in cells exposed to nanomaterial. Thus, 
impaired redox balance may obviously lead to the activation 
of NF-κB.39 Moreover, the generation of high levels of NO, 
followed by the rapid production of other reactive nitrogen 
species, which are the major components of oxidative stress, 
is often considered as an essential mechanism of nanomaterial 
toxicity.40 Prolonged or excessive NO production has delete-
rious effects leading, among others, to serious endothelial 
dysfunction. Interestingly, certain nanoparticles composed 
of cerium oxide, obtained by Selvaraj et al, attenuated iNOS 
expression induced by LPS.41 Also, Ma et al observed that 
exposing mouse macrophage cell line RAW264.7 to gold 
nanoparticles led to downregulation of LPS-induced iNOS 
expression by inhibition of both NF-κB activation and 
IFN-β/STAT1 pathway.42 If the NO synthesis is attenuated, 
the eradication of pathogens may be affected.
We demonstrated that NC6 and NC5-PEG applied to the 
tested cells neither induced iNOS-mediated NO synthesis nor 
influenced the levels of NO produced in response to LPS or 
cytokines. They also did not induce VCAM-1 expression on 
MBE. Endothelial cells, next to RBC and leukocytes, are the 
first to encounter a nanomaterial after its intravenous admin-
istration. Therefore, decreased cell viability or activation of 
endothelium after contact with nanocapsules may provoke 
proinflammatory events. VCAM-1 participates in inflam-
matory response by facilitating migration of immune cells 
to the subintimal space. Some nanoparticles, that is, silica 
nanomaterials, were found to upregulate endothelial expres-
sion of VCAM-1 and other adhesion molecules, increasing 
the risk of development of cardiovascular diseases.43
Although we did not determine NF-κB activation directly, 
the lack of influence of tested nanomaterials on the expres-
sion of two distinct NF-κB–dependent genes indicates that 
polyelectrolyte nanocapsules do not affect this transcription 
factor-mediated inflammatory response.
The toxic effect of numerous nanomaterials is often 
attributed to the generation of ROS followed by subsequent 
perturbations in intracellular signaling and damage of cell 
membrane and DNA that may lead to inflammation or car-
cinogenesis. The mechanism of nanomaterial-induced ROS 
formation may be governed by chemical or physical proper-
ties of the nanoparticles. For metallic nanomaterials, Haber–
Weiss and Fenton reactions are pointed as the main sources of 
ROS, whereas other nanoparticles, including biodegradable 
ones, may lead to oxidative stress by influencing the mito-
chondrial oxidative chain, membrane NADPH oxidase or by 
attenuating the activity of antioxidative enzymes.44,45 There 
are also reports on biodegradable nanoparticles, such as those 
composed of polyoxalate or poly(epsilon-caprolactone), that 
do not induce ROS formation.46
The liver plays an important role in nanomaterial seques-
tration from the blood circulation, followed by its accumula-
tion and degradation. The generation of ROS is indicated as 
a predominant mechanism of nanomaterial hepatotoxicity. 
Thus, to evaluate polyelectrolyte nanocapsule-induced oxi-
dative stress, we used the cell line originating from human 
hepatocytes, HepG2. Both direct assay, which measures ROS 
concentrations in the cells, and indirect assay evaluating 
ROS-induced expression of antioxidative enzymes showed 
that NC6 and NC5-PEG neither stimulated ROS formation 
in HepG2 cells nor affected the antioxidant response.
Nanomaterial-induced oxidative DNA damage has 
already been demonstrated in numerous studies, and oxida-
tive stress is considered as a major mechanism of nanomate-
rial genotoxicity. Therefore, in the light of the above results, 
it is not surprising that polyelectrolyte nanocapsules did not 
induce DNA damage in either tested cells. However, a direct 
measurement of DNA damage as an element of nanomate-
rial testing is highly justified because, as shown by Zijno 
et al, some nanomaterials may potentiate DNA lesions by 
disturbing DNA repair machinery.47 We may classify PGA-
terminated NC6 and NC5-PEG to a group of non-genotoxic 
nanoparticles comprising other biodegradable nanomaterials 
such as biodegradable poly(ε-caprolactone) lipid-core nano-
capsules.48 However, it must be stressed that certain biode-
gradable nanomaterials may induce DNA damage;49 thus, 
genotoxicity must be evaluated for all new biodegradable, 
potentially pharmaceutical, nanomaterials.
Conclusion
Our studies showed that two out of three analyzed biode-
gradable polyelectrolyte nanocapsules, negatively charged, 
six-layer nanocapsules with an external layer composed of 
PGA (NC6) and close-to-neutral, five-layer nanocapsules 
with an external layer composed of the copolymer of PLL and 
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PEG (NC5-PEG), passed all in vitro quality assessments and 
are thus regarded suitable for in vivo testing as potential drug 
carriers. The nanomaterials neither affected the integrity of 
erythrocytes nor promoted the aggregation of PBMCs. They 
also did not 1) affect the viability of any tested cells, including 
PBMCs, P388D1, MBE, HepG2; 2) stimulate inflammatory 
response; 3) stimulate the formation of ROS, or affect the 
activity of antioxidant enzymes or 4) show any genotoxicity. 
Positively charged, PLL-terminated, five-layer nanocapsules 
(NC5) tested at a concentration of ~2×1011/mL were classi-
fied by us as toxic in vitro due to the strong interaction with 
human red blood cells and PBMCs.
Biodegradable nanoparticles are often considered safe 
and are passed for in vivo testing without prior appropriate 
in vitro analyses. The in vitro evaluation is often limited to 
examining their effects on the viability of established cell 
lines. We would like our work to set “a golden standard” for 
testing biocompatible materials, which in our opinion should 
include analyses of their influence on blood cells, ROS forma-
tion, activation of immune response and genotoxicity.
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Supplementary material
Figure S1 Morphology of various cell lines exposed to nanocapsules for 48 hours.
Notes: The cells were grown for 48 hours in a medium containing 1.5 mM Nacl or nanocapsules (~2×1011/ml). Morphological changes were analyzed using the inverted 
light microscope leicaDM Il leD Fluo.
Abbreviations: NC5-PEG, five-layer PEGylated nanocapsules; NC6, six-layer nanocapsules; PEG, polyethylene glycol.
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